0000950170-24-055063.txt : 20240508 0000950170-24-055063.hdr.sgml : 20240508 20240508071511 ACCESSION NUMBER: 0000950170-24-055063 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240508 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240508 DATE AS OF CHANGE: 20240508 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Verve Therapeutics, Inc. CENTRAL INDEX KEY: 0001840574 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 824800132 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40489 FILM NUMBER: 24924234 BUSINESS ADDRESS: STREET 1: 201 BROOKLINE AVENUE STREET 2: SUITE 601 CITY: BOSTON STATE: MA ZIP: 02215 BUSINESS PHONE: (978) 501-3026 MAIL ADDRESS: STREET 1: 201 BROOKLINE AVENUE STREET 2: SUITE 601 CITY: BOSTON STATE: MA ZIP: 02215 8-K 1 verv-20240508.htm 8-K 8-K
false000184057400018405742024-05-082024-05-08

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 8, 2024

Verve Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

Delaware

001-40489

82-4800132

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

201 Brookline Avenue, Suite 601

Boston, Massachusetts

02215

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (617) 603-0070

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common stock, $0.001 par value per share

 

VERV

 

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

On May 8, 2024, Verve Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2024. The full text of the press release issued by the Company in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

The following exhibit is furnished herewith:

 

99.1 Press Release issued by Verve Therapeutics, Inc. on May 8, 2024.

 

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

VERVE THERAPEUTICS, INC.

Date: May 8, 2024

By:

/s/ Allison Dorval

Name: Allison Dorval

Title: Chief Financial Officer

 

 

 

 EX-99.1 2 verv-ex99_1.htm EX-99.1 EX-99.1

Exhibit 99.1

 

img74140242_0.jpg 

Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results

First patient dosed in Heart-2 Phase 1b clinical trial of VERVE-102

VERVE-201 clinical trial initiation on track for the second half of 2024

Received first milestone payment from Eli Lilly for collaboration on an in vivo gene editing program targeting lipoprotein(a) (Lp(a))

Cash, cash equivalents and marketable securities of $606.4 million; cash runway into late 2026

BOSTON — May 8, 2024 — Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today reported pipeline updates and financial results for the quarter ended March 31, 2024.

“Our accomplishments in the first quarter bring us closer to realizing our mission of protecting patients from cardiovascular disease through single-course gene editing medicines. We are excited to investigate VERVE-102 in the Heart-2 clinical trial, having recently announced the first patient dosing in the trial,” said Sekar Kathiresan, M.D., co-founder and chief executive officer of Verve Therapeutics. “We also remain on track to initiate the Phase 1b clinical trial for VERVE-201 targeting ANGPTL3 in the second half of the year and are pleased with the progress we’re making on our Lp(a) collaboration with Eli Lilly. Following these recent achievements and program updates, we are focused on continued execution across our pipeline as we develop our clinical and preclinical programs addressing a robust set of validated targets in areas of high unmet need.”

 

First Patient Dosed with VERVE-102 in Heart-2 Clinical Trial

VERVE-102 is a novel, investigational gene editing medicine designed to be a single course treatment that permanently turns off the PCSK9 gene in the liver to reduce disease-driving low-density lipoprotein cholesterol (LDL-C). VERVE-102 is being developed initially as a treatment for patients with heterozygous familial hypercholesterolemia (HeFH) or premature coronary artery disease (CAD). VERVE-102 consists of messenger RNA expressing an adenine base editor and an optimized guide RNA targeting the PCSK9 gene, identical to VERVE-101. However, VERVE-102 uses a different delivery system than VERVE-101, which includes a different ionizable lipid and Verve’s proprietary GalNAc liver-targeting ligand, which allows the lipid nanoparticle (LNP) to access liver cells using either the asialoglycoprotein receptor (ASGPR) or the low-density lipoprotein receptor (LDLR).

Verve recently dosed its first patient in the Heart-2 Phase 1b clinical trial. Heart-2 is an open-label Phase 1b clinical trial designed to evaluate the safety and tolerability of VERVE-102 in adult patients with HeFH or premature CAD who require additional lowering of LDL-C, with additional analyses for pharmacokinetics and changes in blood PCSK9 protein and LDL-C levels. The company received clearances of its Clinical Trial Applications (CTAs) in Canada and the U.K. Verve expects to provide a data update on the PCSK9 program in 2025.

Ongoing Analysis of Heart-1 Clinical Trial of VERVE-101

Enrollment remains paused in the Heart-1 trial as Verve continues to investigate the observed laboratory abnormalities which Verve believes are attributable to the LNP delivery system. As the company continues to work with regulatory authorities to define a potential path forward, the VERVE-101 Investigational New Drug Application (IND) in the U.S. and CTAs in the U.K. and New Zealand remain active.

VERVE-201 on Track for Clinical Trial Initiation in Second Half of 2024

VERVE-201, an in vivo base editing medicine delivered as a one-time intravenous infusion, is designed to inactivate the ANGPTL3 gene in liver cells, turning off liver production of blood ANGPTL3 protein and thereby durably reducing blood LDL-C and triglyceride-rich lipoproteins. For VERVE-201, Verve is utilizing its proprietary GalNAc-LNP delivery technology. VERVE-201 is being developed for the treatment of patients living with homozygous familial hypercholesterolemia (HoFH), a rare and often fatal inherited subtype of premature accelerated atherosclerotic cardiovascular disease (ASCVD) characterized by

extremely high blood LDL-C. VERVE-201 aims to reduce the heavy treatment burden associated with available therapies for HoFH, including the requirement for multiple oral, injectable, and intravenous infusions, often administered over decades. VERVE-201 is also being developed for ASCVD patients with refractory hypercholesterolemia, who have high LDL-C despite treatment with maximally-tolerated standard of care therapies.

Verve has completed preclinical studies to support regulatory submissions for clinical development. Verve expects to initiate the VERVE-201 Phase 1b clinical trial in the second half of 2024, subject to regulatory clearances.

 

First Milestone Achieved in Global Collaboration with Eli Lilly

Verve achieved its first research and development milestone related to its exclusive research collaboration with Eli Lilly focused on advancing Verve’s research stage in vivo gene editing program targeting LPA. Elevated Lp(a) is an established and genetically validated, independent risk factor for ASCVD, ischemic stroke, and aortic stenosis.

Under the terms of the collaboration established in June 2023, Verve will advance the research and development of the Lp(a) program through the completion of Phase 1 clinical development. Lilly will be responsible for subsequent development, manufacturing, and commercialization of the Lp(a) program. Verve is eligible to receive up to $465 million in research, development, and commercial milestones, as well as tiered royalties on global net sales. Following the completion of Phase 1 clinical trials, Verve has the right to opt-in to co-fund and share margins globally on the Lp(a) program (in lieu of receipt of milestones and royalties).

 

Upcoming Medical Meeting Presentations

American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting: Verve will present an overview of off-target analyses for VERVE-101.

Presentation title: Characterization of Guide RNA Site Consistency Across Ancestries and the Potential for Off-Target Editing with the Clinical Stage Base Editing Medicine, VERVE-101

Track: Base Editing and Prime Editing II

Date/time: Saturday, May 11, 2024, 10:30 – 10:45 a.m. ET

Location: Ballroom 3, Baltimore Convention Center, Baltimore, MD

 

TIDES 2024: Verve will present previously disclosed nonclinical and clinical data from the company’s PCSK9 program.

Presentation title: Proof-of-concept for in vivo Base Editing to Inactivate the PCSK9 Gene and Lower LDL-Cholesterol in Humans

Track: Genome Editing Technology and Applications

Date/time: Friday, May 17, 2024, 11:15 – 11:45 a.m. ET

Location: Hynes Convention Center, Boston, MA

 

Upcoming Investor Event

Verve plans to participate in a fireside chat at the RBC Global Healthcare Conference on Wednesday, May 15, 2024, at 8:00 a.m. ET in New York.

A live webcast will be available in the investor section of the company’s website at www.vervetx.com. The webcast will be archived for 30 days following the presentation.

 

First Quarter 2024 Financial Results

 

Cash Position: Verve ended the first quarter of 2024 with $606.4 million in cash, cash equivalents, and marketable securities. Verve continues to expect its capital position to be sufficient to fund its operations into late 2026.

 

Collaboration Revenue: Collaboration revenue was $5.7 million for the first quarter of 2024, compared to $1.4 million for the first quarter of 2023. The increase was primarily due to an increase in research services performed under the company’s collaboration agreements and cost reimbursements.

 

Research & Development (R&D) Expenses: R&D expenses were $48.4 million for the first quarter of 2024, compared to $47.1 million for the first quarter of 2023. Stock-based compensation expense included in R&D expenses was $5.6 million and $4.5 million for the first quarter of 2024 and 2023, respectively.

 

General & Administrative (G&A) Expenses: G&A expenses were $14.2 million for the first quarter of 2024, compared to $12.6 million for the first quarter of 2023. Stock-based compensation expense included in G&A expenses was $4.7 million and $3.5 million for the first quarter of 2024 and 2023, respectively.

 

Net Loss: Net loss was $48.7 million, or $0.59 basic and diluted net loss per share, for the first quarter of 2024, compared to $52.0 million, or $0.84 basic and diluted net loss per share, for the first quarter of 2023.

 

About Verve Therapeutics

Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage genetic medicines company pioneering a new approach to the care of cardiovascular disease, potentially transforming treatment from chronic management to single-course gene editing medicines. The company’s lead programs – VERVE-101, VERVE-102, and VERVE-201 – target genes that have been extensively validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of atherosclerotic cardiovascular disease (ASCVD). VERVE-101 and VERVE-102 are designed to permanently turn off the PCSK9 gene in the liver and are being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat patients with established ASCVD who continue to be impacted by high LDL-C levels. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for homozygous familial hypercholesterolemia (HoFH) and for refractory hypercholesterolemia where patients still have high LDL-C despite treatment with maximally-tolerated standard of care therapies. For more information, please visit www.VerveTx.com.

Cautionary Note Regarding Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the company’s ongoing Heart-2 clinical trial; the timing and availability of data for the PCSK9 program; expectations for the company’s Heart-1 clinical trial, including the company’s assessment of the laboratory abnormalities observed in the trial and the company’s interactions with regulatory authorities regarding VERVE-101; the receipt of regulatory clearances and expected timing of initiating the clinical trial of VERVE-201; its research and development plans; the potential advantages and therapeutic potential of the company’s programs; the potential milestone payments and potential royalties on future sale under the Lilly collaboration; the potential co-fund and margin share arrangement under the Lilly collaboration; and the period over which the company believes that its existing cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses. All statements, other than statements of historical facts, contained in this press release, including statements regarding the company’s strategy, future operations, future financial position, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with the company’s limited operating history; the company’s ability to timely submit and receive approvals of regulatory applications for its product candidates; advance its product candidates in clinical trials; initiate, enroll and complete its ongoing and future clinical trials on the timeline expected or at all; correctly estimate the potential patient population and/or market for the company’s product candidates; replicate in clinical trials positive results found in preclinical studies and/or earlier-stage clinical trials of VERVE-101, VERVE-102, and VERVE-201; advance the development of its product candidates under the timelines it anticipates in current and future clinical trials; obtain, maintain or protect intellectual property rights related to its product candidates; manage expenses; and raise the substantial additional capital needed to achieve its business objectives. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the company’s actual results to differ from those contained in the forward-looking statements, see the “Risk Factors” section, as well as discussions of potential risks, uncertainties and other important factors, in the company’s most recent filings with the Securities and Exchange Commission and in other filings that the company makes with the Securities and Exchange Commission in the future. In addition, the forward-looking statements included in this press release represent the company’s views as of the date hereof and should not be relied upon as representing the company’s views as of any date subsequent to the date hereof. The company anticipates that subsequent events and developments will cause the company’s

views to change. However, while the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so.

Investor Contact
Jen Robinson
Verve Therapeutics, Inc.
jrobinson@vervetx.com

Media Contact
Ashlea Kosikowski

1AB

ashlea@1abmedia.com

Verve Therapeutics, Inc.

 

Selected Condensed Consolidated Financial Information

 

(in thousands, except share and per share amounts)

 

(unaudited)

 

 

 

Three months ended March 31,

 

Condensed consolidated statements of operations

 

 

2024

 

 

 

2023

 

 

 

 

 

 

 

 

Collaboration revenue

 

$

5,695

 

 

$

1,404

 

Operating expenses:

 

 

 

 

 

 

Research and development

 

 

48,376

 

 

 

47,110

 

General and administrative

 

 

14,163

 

 

 

12,553

 

Total operating expenses

 

 

62,539

 

 

 

59,663

 

Loss from operations

 

 

(56,844

)

 

 

(58,259

)

Other income:

 

 

 

 

 

 

Change in fair value of success payment liability

 

 

78

 

 

 

738

 

Interest and other income, net

 

 

8,136

 

 

 

5,546

 

Total other income, net

 

 

8,214

 

 

 

6,284

 

Loss before provision for income taxes

 

 

(48,630

)

 

 

(51,975

)

Provision for income taxes

 

 

(106

)

 

 

—

 

Net loss

 

 

(48,736

)

 

 

(51,975

)

Net loss per common share, basic and diluted

 

$

(0.59

)

 

$

(0.84

)

Weighted-average common shares used in net loss per share, basic and diluted

 

 

83,132,960

 

 

 

61,787,403

 

 

 

Condensed consolidated balance sheet data

 

March 31,
2024

 

 

December 31,
2023

 

Cash, cash equivalents and marketable securities

 

$

606,367

 

 

$

623,950

 

Total assets

 

$

732,357

 

 

$

752,688

 

Total liabilities

 

$

149,288

 

 

$

153,186

 

Total stockholders' equity

 

$

583,069

 

 

$

599,502

 

 

 

 

 

 

 

 

 

 GRAPHIC 3 img74140242_0.jpg GRAPHIC begin 644 img74140242_0.jpg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end EX-101.SCH 4 verv-20240508.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Address, State or Province Entity Address, State or Province Trading Symbol Trading Symbol Soliciting Material Soliciting Material Entity Address, City or Town Entity Address, City or Town Written Communications Written Communications Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity Registrant Name Entity Registrant Name Entity Ex Transition Period Entity Ex Transition Period Document Period End Date Document Period End Date Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Local Phone Number Local Phone Number City Area Code City Area Code Pre-commencement Tender Offer Pre-commencement Tender Offer Cover [Abstract] Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Amendment Flag Amendment Flag Securities Act File Number Entity File Number Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line One Entity Address, Address Line One Title of 12(b) Security Title of 12(b) Security Document Type Document Type XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Document And Entity Information
May 08, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 08, 2024
Entity Registrant Name Verve Therapeutics, Inc.
Entity Central Index Key 0001840574
Entity Emerging Growth Company false
Entity File Number 001-40489
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 82-4800132
Entity Address, Address Line One 201 Brookline Avenue
Entity Address, Address Line Two Suite 601
Entity Address, City or Town Boston
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02215
City Area Code (617)
Local Phone Number 603-0070
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, $0.001 par value per share
Trading Symbol VERV
Security Exchange Name NASDAQ
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.vervetx.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports verv-20240508.htm verv-20240508.xsd http://xbrl.sec.gov/dei/2023 false false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "verv-20240508.htm": { "nsprefix": "verv", "nsuri": "http://www.vervetx.com/20240508", "dts": { "inline": { "local": [ "verv-20240508.htm" ] }, "schema": { "local": [ "verv-20240508.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://www.vervetx.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_3fc9656b-1b1e-4553-bb61-183555146a52", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "verv-20240508.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3fc9656b-1b1e-4553-bb61-183555146a52", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "verv-20240508.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.vervetx.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.vervetx.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.vervetx.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.vervetx.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.vervetx.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.vervetx.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.vervetx.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.vervetx.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.vervetx.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.vervetx.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.vervetx.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.vervetx.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.vervetx.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.vervetx.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.vervetx.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.vervetx.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.vervetx.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.vervetx.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.vervetx.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.vervetx.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.vervetx.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.vervetx.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.vervetx.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.vervetx.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0000950170-24-055063-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-055063-xbrl.zip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end XML 16 verv-20240508_htm.xml IDEA: XBRL DOCUMENT 0001840574 2024-05-08 2024-05-08 false 0001840574 8-K 2024-05-08 Verve Therapeutics, Inc. DE 001-40489 82-4800132 201 Brookline Avenue Suite 601 Boston MA 02215 (617) 603-0070 false false false false Common stock, $0.001 par value per share VERV NASDAQ false